Acurx Pharmaceuticals (ACXP) Cash from Operations (2020 - 2026)
Acurx Pharmaceuticals' (ACXP) quarterly Cash from Operations came in at 1407533.0 in Q1 2026, up 31.39% YoY from 1071263.23 in Q1 2025, and down 18.81% on a QoQ basis from 1184740.0 in Q4 2025.
Acurx Pharmaceuticals (ACXP) Cash from Operations (2020 - 2026) Analysis & Trends
Acurx Pharmaceuticals (ACXP) has 7 years of Cash from Operations data on file, last reported at 1407533.0 in Q1 2026.
- Quarterly Cash from Operations rose 31.39% year-over-year to 1407533.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 6143816.0 (up 34.44% YoY) and the FY2025 annual result came in at 6787782.0, up 34.63% from the prior year.
- Cash from Operations retreated to 1407533.0 in Q1 2026, from 1184740.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 1184740.0 in Q4 2025 to a low of 4197778.0 in Q4 2023.
- A 5-year average of 2113054.18 and a median of 1990649.0 in 2022 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations sank 503.58% — and 2025, when it jumped 47.35%.
- Tracing ACXP's Cash from Operations over 5 years: stood at 1495589.0 in 2022, then sank by 180.68% to 4197778.0 in 2023, then surged by 46.39% to 2250398.0 in 2024, then soared by 47.35% to 1184740.0 in 2025, then retreated by 18.81% to 1407533.0 in 2026.
- The last three Cash from Operations figures came in at 1407533.0 (Q1 2026), 1184740.0 (Q4 2025), and 1880969.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.54 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.13 Bn | 78.13 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 65.58 Bn | 60.40 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 27.97 Bn | 9.58 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 728.46 Mn |
| 10 | Acurx Pharmaceuticals | 6.30 Mn | 6.30 Mn | - | -1.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.71 Mn |
| Jun 30, 2026 | -1.71 Mn |
| Mar 31, 2026 | -1.41 Mn |
| Mar 31, 2026 | -1.41 Mn |
| Dec 31, 2025 | -1.18 Mn |
| Dec 31, 2025 | -1.18 Mn |
| Sep 30, 2025 | -1.88 Mn |
| Sep 30, 2025 | -1.88 Mn |
| Jun 30, 2025 | -1.67 Mn |
| Jun 30, 2025 | -1.67 Mn |
| Mar 31, 2025 | -2.05 Mn |
| Mar 31, 2025 | -2.05 Mn |
| Dec 31, 2024 | -2.25 Mn |
| Dec 31, 2024 | -2.25 Mn |
| Sep 30, 2024 | -2.19 Mn |
| Sep 30, 2024 | -2.19 Mn |
| Jun 30, 2024 | -2.88 Mn |
| Jun 30, 2024 | -2.88 Mn |
| Mar 31, 2024 | -3.06 Mn |
| Mar 31, 2024 | -3.06 Mn |